News News – 2020 [BioWorld Interview] Hummingbird taps Tempus’ AI for clinical trial in rare NRG1 fusion patients Continue Reading
News News – 2020 Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-Driven Precision Medicine to Accelerate Clinical Development of HMBD-001 in HER3-Driven Cancers Including NRG1 Fusions Continue Reading
News News – 2020 Singapore biotech firm hopes for ‘widespread’ release of new Covid-19 treatment by early 2021 Continue Reading
News News – 2020 [Herald Interview] Singaporean antibody firm draws throngs of Korean investors Continue Reading
News News – 2020 [Herald Interview] Singaporean antibody firm draws throngs of Korean investors Continue Reading
News News – 2020 Hummingbird Bioscience Scientific Advisory Board member Prof. John Connolly appointed as Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy Continue Reading
News News – 2020 Hummingbird Bioscience Closes US$25 Million Investment With Series B Extension Continue Reading
News News – 2019 Hummingbird Bioscience raises $19 Million in Series B financing to support expansion of its discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics Continue Reading
News News – 2019 Hummingbird Bioscience Announces Collaboration with Amgen to Co-Discover Novel Therapeutics Using Hummingbird’s Rational Antibody Discovery Platform Continue Reading
News News – 2019 Cancer Research UK and Hummingbird Bioscience Join Forces to Advance Novel Antibody Drug into Clinical Trials Continue Reading
